Ossenkoppele, Gert

Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome

Grob, T., Al Hinai, A. S. A., Sanders, M. A., Kavelaars, F. G., Rijken, M., Gradowska, P. L., Biemond, B. J., Breems, D. A., Maertens, J., van Marwijk Kooy, M., et al. (2022) · Blood

Acute Myeloid Leukemia ResearchCancer Genomics and Diagnostics

Cited by 305

Aberrant marker expression patterns on the CD34+CD38− stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission

van Rhenen, A., Moshaver, B., Kelder, A., Feller, N., Nieuwint, A. W. M., Zweegman, S., Ossenkoppele, G. J., & Schuurhuis, G. J. (2007) · Leukemia

Acute Myeloid Leukemia ResearchHematopoietic Stem Cell Transplantation

Cited by 193

The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia

Pfirrmann, M., Clark, R. E., Prejzner, W., Lauseker, M., Baccarani, M., Saussele, S., Guilhot, F., Heibl, S., Hehlmann, R., Faber, E., et al. (2020) · Leukemia

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 96

Positioning of aminopeptidase inhibitors in next generation cancer therapy

Hitzerd, S. M., Verbrugge, S. E., Ossenkoppele, G., Jansen, G., & Peters, G. J. (2014) · Amino Acids

Peptidase Inhibition and AnalysisProtease and Inhibitor Mechanisms

Cited by 95

Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin

Lauseker, M., Bachl, K., Turkina, A., Faber, E., Prejzner, W., Olsson‐Strömberg, U., Baccarani, M., Lomaia, E., Zackova, D., Ossenkoppele, G., et al. (2019) · American Journal of Hematology

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 28